Trafermin

Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers.^[2][3][1] It is also currently in preregistration for the treatment of periodontitis.^[2][4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4.^[5][6] The drug has been marketed in Japan since June 2001.^{[citation needed]}

Trafermin

Clinical data
Trade names	Fiblast
Other names	CAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced)
Routes of administration	Topical (spray)[1]
ATC code	D03AX15 (WHO)
Identifiers
CAS Number	131094-16-1
PubChem SID	17397511
ChemSpider	none
UNII	333OX80X87
KEGG	D03362
Chemical and physical data
Formula	C764H1201N217O219S6
Molar mass	17122.67 g·mol−1